ENDOTHELIAL PROTECTION IN THE REHABILITATION OF PATIENTS WITH POSTSTROKE APHASIA

DOI: https://doi.org/10.29296/25877305-2018-03-07
Download full text PDF
Issue: 
3
Year: 
2018

V. Shishkova, Candidate of Medical Sciences; A. Remennik; L. Zotova Center for Speech Pathology and Neurorehabilitation, Moscow

An open randomized controlled study was conducted to comprehensively examine the dynamics of recovery of speech functions and to simultaneously estimate the level of markers for endothelial dysfunction in patients with prior ischemic stroke when naftidrofuryl (Duzofarm) is incorporated into the treatment regimen.

Keywords: 
cardiology
neurology
stroke
poststroke aphasia
rehabilitation
naftidrofuryl (Duzofarm)



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Redon J., Olsen M., Cooper R. et al. Stroke mortality trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure // Eur. Heart J. – 2011; 32: 1424–31.
  2. Gusev E.I., Skvortsova V.I., Stahovskaja L.V. Problema insul'ta v Rossijskoj Federatsii: vremja aktivnyh sovmestnyh dejstvij // Zhurn. nevrol. i psihiat. – 2007; 8: 4–10.
  3. Libby P., Ridker P., Hansson G. Information in atherosclerosis from pathophysiology to practice // J. Am. Coll. Cardiol. – 2009; 54: 2129–38.
  4. Muller W. Mechanisms of transendothelial migration of leukocytes // Circ. Res. – 2009; 105 (3): 223–30.
  5. Zarbock A., Ley K. Neutrophil adhesion and activation under flow // Microcirculation. – 2009; 16 (1): 31–42.
  6. Luscher T., Noll G. The endothelium as a regulator of vascular tone and growth. The endothelium in cardiovascular disease: pathophysiology, clinical presentation, and pharmacotherapy / Berlin, 1995; p. 1–24.
  7. Poncin-Lafitte M., Grosdemouge C., Roy-Billon C. et al. Effects of naftidrofuryl on cerebral hemodynamics. metabolism and function after a retracted ischaemia // Arch. Int. Pharmacodyn. Ther. – 1982; 260 (2): 218–29.
  8. Oudart N. Naftidrofuryl inhibits contractions to serotoninin intact and de-endothelialized cerebral arteries in vitro // J. Cardiovasc. Pharmacol. – 1990; 16 (Suppl. 3): 45–8.
  9. Wiemsperger N. Serotonin, 5HT receptors and brain circulation // J. Cardiovasc. Pharmacol. – 1990; 16 (Suppl. 3): 20–4.
  10. Lagrue G., Questel R. Indirect evaluation of blood oximetry by digitized conjunctival capillarography: effects of naftidrofuryl // J. Cardiovasc. Pharmacol. – 1990; 16 (Suppl. 3): 67–71.
  11. Zander J., Aarhus L., Katusic Z. et al. Effects of naftidrofuryl on adrenergic nerves, endothelium and smooth muscle inisolated canine blood vessels // J. Pharmacol. Exp. Ther. – 1986; 239 (3): 760–7.
  12. Lepetit J., Dumond D., Gros J. Controle de l'activite du naftidrofuryl a la phase aigue des AVC par I'echopulsographietranscerebrale // Psychol. Med. – 1992; 24: 975–82.
  13. Kirsten R., Erdeg B., Moxter D. et al. Platelet aggregation after naftidrofuryl application in vitro and ex vivo // Int. J. Clin. Pharmacol. Ther. – 1995; 33 (2): 81–4.
  14. Herrmann K., Grosse-Heitmeyer A., Kreuzer H. Antithrombotic efficacy and its time course after application of naftidrofuryl in vivo // Arch. Int. Pharmacodyn. Ther. – 1986; 284 (1): 145–54.
  15. Takeo S., Tanonaka R., Miyake K. et al. Naftidrofuryl oxalate improves impaired brain glucose metabolism after induced cerebral metabolism in rats // J. Pharmacol. Exp. Ther. – 1991; 257 (1): 404–10.
  16. Wiernsperger N. Serotonin, 5-HT2 receptors, and their blockade by naftidrofuryl: a targeted therapy of vascular disease // J. Cardiovasc. Pharmacol. – 1994; 23 (Suppl. 3): 37–43.
  17. Taguchi T., Takagi N., Miyake K. et al. Effects of naftidrofuryl oxalate on microsphereinduced changes in acetylcholine and amino acid content of rat brain regions // Exp. Brain Res. – 1994; 99 (1): 7–16.
  18. Louis J. Effect of naftidrofuryl on metabolism and survival of cultured neurons // Neurochem. Res. – 1989; 14 (12): 1195–201.
  19. Skvortsova V.I. Printsipy rannej reabilitatsii bol'nyh s insul'tom // Zhurn. nevrol. i psihiat. (Pril.: «Insul't»). – 2002; 7: 28–33.
  20. Burns M. Application of Neuroscience to Technology in Stroke Rehabilitation // Top Stroke Rehabil. – 2008; 15: 570–9.
  21. Luk'janjuk E.V., Shklovskij V.M., Maljukova N.G. Opyt primenenija akatinolamemantina v rezidual'nom periode insul'ta // Zhurn. nevrol. i psihiat. (Pril.: «Insul't»). – 2010; 12: 28–33.
  22. Shishkova V.N, Zotova L.I., Kan N.V. i dr. Otsenka effektivnosti naftidrofurila v sostave rannej kompleksnoj reabilitatsii u patsientov s postinsul'tnoj afaziej // Vrach. – 2017; 7: 47–50.
  23. Shishkova V.N., Shklovskij V.M., Remennik A.Ju. i dr. Novye vozmozhnosti otsenki nejroreabilitatsionnogo potentsiala u patsientov s postinsul'tnoj afaziej // Med. alfavit. – 2016; 1: 25–9.
  24. Adhoute G., Barcourt F., Barral M. et al. Naftidrofuryl in chronic arterial disease: results of a sixmonth controlled multicenter study using Naftidrofuril tablets 200 mg // Angiology. – 1994; 35: 701–8.
  25. Lu D., Song H., Hao Z. et al. Naftidrofuryl for dementia (Review) // Cochrane Database Syst. Rev. – 2011; 12: CD002955. DOI: 10.1002/14651858.CD002955.pub4.
  26. de Backer T., Vander Stichele R., Lehert P. et al. Naftidrofuryl for intermittent claudication // Cochrane Database Syst. Rev. – 2012; 12: CD001368.
  27. Zolotovskaja I.A., Davydkin I.L. Vozmozhnosti farmakologicheskoj korrektsii strukturno-funktsional'nyh izmenenij v uslovijah endotelial'noj disfunktsii u komorbidnyh patsientov, perenesshih insul't // Klinitsist. – 2016; 2: 32–42.